Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT05471843 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT05471843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05471843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Lead sponsor
BeOne Medicines
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 5, 2022
Completion date
January 31, 2027
Enrollment
125 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma, refractory mantle cell lymphoma (mcl), relapsed mantle cell lymphoma